Genedata and Abcam expand partnership to enhance antibody development

BASEL, Switzerland, Sept. 3, 2026, Genedata, a leading provider of enterprise software for biopharmaceutical R&D, has announced an expanded partnership with Abcam, a global provider of validated antibodies and assay solutions. The collaboration aims to enhance data connectivity, accelerate innovation, and support the development of high-quality reagents for researchers.

By deploying Genedata Biologics® across Abcam's global R&D organization, the two Danaher companies are working to strengthen antibody development capabilities and unlock the full value of scientific data. The platform has been implemented at Abcam's headquarters in the UK and key sites in China and the US, creating a unified data foundation that connects global, cross-functional teams.

Kaveh Kahen, PhD, President of Abcam, stated, "As researchers seek high-quality antibodies across a growing range of targets and applications, it is essential that we continue to scale and evolve our development capabilities to meet their needs. By building on Genedata's world-class platform, we benefit from automation, connectivity, and flexibility needed to support our global R&D operations."

Genedata Biologics provides a digital backbone for Abcam's antibody development pipeline, which delivers approximately 500 new antibodies to the market each year. The platform enables teams to manage complex workflows, track sample history, and capture and analyze antibody characterization data within a secure, structured environment. By integrating data, processes, and teams, Abcam can work more efficiently and advance promising candidates faster, helping researchers gain access to the high-quality antibodies they need sooner.

Othmar Pfannes, PhD, President of Genedata, said, "Abcam and Genedata share a commitment to applying data and technology to accelerate scientific innovation. By combining Abcam's deep expertise in antibody development with the Genedata Biologics platform, we are creating an environment where Abcam's scientific teams can collaborate more effectively, generate actionable insights at scale, and build on a strong foundation for AI-powered discovery. The ultimate beneficiaries are researchers, who gain faster access to the validated reagents that support high-quality scientific outcomes."

The partnership is expected to drive significant advancements in the field of antibody development, leveraging the strengths of both companies to enhance research efficiency and quality. Abcam's focus on providing expert scientific support and highly validated antibodies, along with Genedata's enterprise software solutions, positions them to deliver cutting-edge reagents to the scientific community.

Through this collaboration, Abcam and Genedata aim to support the scientific community by accelerating the discovery and development of high-quality antibodies, ultimately contributing to the advancement of research in areas such as cancer, neurological disorders, infectious diseases, and metabolic disorders.